The Retention Revolution: Travel is the primary reason for a 30% patient dropout rate. Moving the clinical site to the patient's home removes this significant barrier.
ICH E6(R3) Readiness: Australia's Therapeutic Goods Administration (TGA) is aligning with the 2026 shift to updated global standards which require a Quality by Design approach.
Unbroken Chain of Custody: Keeping unapproved medicines stable outside a clinic requires IoT sensors and specialised delivery to maintain the cold chain.
Scalable Compliance: Success in Australia means handling a patchwork of state-based regulations and reaching patients in remote locations.
Traditional site-centric models of research are hitting a wall in 2026. Recruitment goals are often missed because patients cannot manage the time and travel for hospital or clinic visits. We've built the DHL Health Logistics network to solve this challenge directly. Our 2-billion-euro investment ensures you have the GDP-certified infrastructure and specialised handling needed to reach patients anywhere in Australia. Direct-to-Patient (DtP) clinical trials move the laboratory to the living room while keeping the highest levels of safety.
Travel is the main reason participants leave clinical studies. When you move the trial site to the patient, you reduce missed visits and screen failures, which is critical for meeting study timelines.
Travel Distance: Cancer trial patients travel a median of nearly 42 miles for Phase I studies.
Rural Hurdles: For participants in remote areas of states like Western Australia or Queensland, travel can easily exceed 100 kilometres each way.
Human Connection: Technical couriers act as a professional extension of the clinical site at the patient's doorstep.
Supportive Experience: These white-glove services go beyond simple delivery to build participant trust and confidence in the trial.
DHL Health Logistics provides the professional bridge between your lab and the participant. We understand that a courier is often the only face of the trial that a patient sees.
Australian regulators are updating their rules to support decentralised models. The new ICH E6(R3) guidelines, overseen by the Therapeutic Goods Administration (TGA), require you to prove the drug stayed stable from the depot to the patient’s refrigerator.
Transition Period: Australia has a 12-month transition for ICH E6(R3) starting in January 2026, meaning sponsors must have compliant processes ready.
Strict Accountability: The TGA's good clinical practice (GCP) guidelines demand robust temperature records for the entire supply chain.
Thermal Protection: Advanced shippers maintain critical temperatures of 2 to 8°C or -20°C for up to 120 hours, essential for long-haul deliveries across the country.
Digital Proof: IoT sensors transmit live data, providing an auditable record of when a participant received the shipment and its condition on arrival.
Our investment in digital tools ensures you have a full thermal audit trail. This transparency is a non-negotiable requirement for satisfying quality assurance teams and TGA inspectors in 2026.
While Australia has a clear federal framework under the TGA, delivering unapproved medicines to a private address still requires careful navigation of state and territory-level health regulations. You need a partner who understands the complete compliance picture.
State-Level Nuances: Each state's health department can have specific requirements for pharmacy services and the handling of clinical materials.
Navigating Approvals: The TGA's Clinical Trial Approval (CTA) scheme provides a robust pathway for trials involving unapproved therapeutic goods.
Expert Navigation: Our local specialists work directly with the TGA to ensure your trial protocols meet all national and state requirements, keeping your study on track.
Expanded Footprint: Proper licensing and logistics planning allow you to include participants in regional and remote areas that were previously considered too complex to service.
Security and privacy are vital when delivering sensitive therapeutic goods to a home. You must have a process to ensure the medicine is handed directly to the verified participant or their legal representative.
Identity Verification: We check government-issued IDs against trial records before any package is handed over.
Point-of-Use Delivery: Couriers can place the medication directly into the participant’s designated storage area or refrigerator.
Instruction Support: We confirm the patient understands how to handle the packaging and any immediate storage steps.
Safe Disposal: Our service includes collecting used kits or sharp containers for compliant medical-grade destruction.
A DtP trial does not end at the doorstep. You must also manage the time-sensitive flow of biological samples and unused drugs from the patient back to the central lab.
Stability Windows: Blood or urine samples must be collected and returned to the lab within strict time limits to be viable.
Data Integrity: If a biological sample is exposed to heat during transit from a remote location to a lab in Sydney or Melbourne, the trial data is ruined.
Remote Reach: We use specialised transport and pre-conditioned packaging to reach participants anywhere in Australia, from the outback to regional town centres.
Unified Visibility: A clinical research associate in Sydney should see the same real-time tracking data as a sponsor in London.
Direct-to-Patient logistics is no longer just a future concept. It’s the most effective way to improve the patient experience and protect your data integrity. DHL Health Logistics is ready to help you scale your research across Australia. Speak to a DHL specialist today to check your trial plan and reach your participants with confidence.
They remove the significant physical and time burden of travel by delivering medicine directly to the participant's home. This makes it far easier for patients, especially those in rural or regional areas, to stay in the study while maintaining their daily routines.
These 2026 guidelines require sponsors to use a Quality by Design approach. For Australian trials, this means you must have verifiable digital proof for the TGA that your investigational products stayed stable throughout the entire journey to the patient.
We use real-time IoT sensors inside the shipment that transmit live location and thermal data to a central dashboard. This ensures your clinical team receives an immediate alert if the shipment deviates from its required temperature range.
Yes, but it requires a partner that understands how to manage both federal TGA regulations and state-specific health requirements. Using a standardised digital platform like MyDHL+ ensures your data and processes remain consistent and comparable, whether the patient is in Perth or Parramatta.
Yes, our couriers perform a strict, verified delivery protocol. This includes checking the participant's ID against the trial manifest to ensure the sensitive medication is handed directly to the correct person.
Share
